Substance + claimed effects

Acne vulgaris in adolescence is the chronic inflammatory disease of the pilosebaceous unit that follows the androgen surge of puberty. Four interlocking processes drive it: androgen-stimulated sebum hypersecretion, abnormal keratinocyte shedding inside the follicle that plugs the pore, proliferation of Cutibacterium acnes in the sebum-rich plug, and a Th17 / IL-1 / TLR2-driven inflammatory response that produces papules, pustules, and nodules Reynolds 2024Mirdamadi 2024. Globally, ~85% of 12–24-year-olds are affected; in clinic-relevant moderate-to-severe form, roughly a fifth Bhate & Williams 2013Tan & Bhate 2015Heng & Chew 2020. This entry covers what the disease is doing biologically, the staged topical-to-systemic treatment ladder (benzoyl peroxide + topical retinoid, oral antibiotics, hormonal therapy for females, isotretinoin), and the consequences that follow: cumulative beauty (scarring, post-inflammatory pigment), short-term wellness (skin pain, picking lesions), mood and inner wellbeing (depression, social anxiety, suicidal ideation), and the social-functioning hit that compounds during the years self-image is being built.

Evidence by addressing question

mechanism

The trigger is adrenarche / gonadarche: adrenal DHEA-S rises from ~age 7–8, gonadal androgens from ~age 10–13, and the sebaceous glands (rich in 5α-reductase and androgen receptors) hypertrophy in response, producing sebum at several times the pre-pubertal rate Reynolds 2024Eichenfield 2013. In parallel, the keratinocytes lining the follicular infundibulum stop shedding cleanly — they cohere into a microplug (the microcomedone, the precursor lesion of every comedone, papule, and pustule). The sebum-filled microenvironment selects for lipase-producing strains of Cutibacterium acnes (renamed from Propionibacterium acnes in 2016) that form biofilms, hydrolyse triglycerides into pro-inflammatory free fatty acids, and activate the innate immune system via TLR2 — driving the IL-1α / IL-8 / IL-17 cascade that turns a closed comedone into a red papule, then pustule, then nodule when the follicle wall ruptures into the dermis Mirdamadi 2024Reynolds 2024. Inflammation is now understood to be present from the microcomedone stage, not a late-stage event — which is why every modern topical that works targets it (benzoyl peroxide's anti-microbial and anti-inflammatory action; retinoids' normalisation of keratinocyte turnover and direct anti-inflammatory effect via AP-1 inhibition).

evidence

The treatment ladder is among the best-evidenced in dermatology. Benzoyl peroxide is supported by ≥40 RCTs since the 1970s; consistent reductions in inflammatory and non-inflammatory lesion counts of roughly 50% at 12 weeks, with no bacterial resistance documented (oxidative mechanism prevents adaptation) Reynolds 2024. Topical retinoids (tretinoin, adapalene, tazarotene, trifarotene) reduce comedonal and inflammatory lesions by 40–70% at 12 weeks across multiple RCTs; adapalene 0.1% is the best-tolerated and OTC in the US since 2016 Reynolds 2024Tan 2017. The benzoyl-peroxide + topical-retinoid combination is faster and more effective than either alone and is the AAD's strong-evidence first-line for almost all severities. Oral antibiotics (doxycycline, minocycline, sarecycline) reduce moderate-to-severe acne, but the effect plateaus by 3–4 months and resistance develops; the guideline therefore caps duration at ~3 months and requires concurrent benzoyl peroxide Reynolds 2024NICE 2023. Combined oral contraceptives reduce inflammatory and non-inflammatory lesions in females by 30–55% versus placebo at 6 months (Cochrane review of 31 RCTs, n>12,000) Arowojolu 2012. Spironolactone reduced acne severity in the SAFA RCT (n=410 adult women) versus placebo with NNT ~5 Layton 2020. Isotretinoin — the only treatment that can produce durable remission — delivers complete clearance in 85% at standard cumulative doses of 120–150 mg/kg, with ~20% relapse requiring a second course Reynolds 2024Zaenglein 2016.

protocol

The current AAD framework is severity-staged and starts everyone on combination topicals, escalating only when needed Reynolds 2024NICE 2023:

• Mild (comedonal ± few inflamed lesions): benzoyl peroxide 2.5–5% once daily + topical retinoid (adapalene 0.1% OTC, tretinoin 0.025–0.05% Rx) at night. Topical clindamycin may be added but never as monotherapy. Reassess at 12 weeks.
• Moderate (many inflammatory papules / pustules, truncal involvement): above plus oral doxycycline 50–100 mg/day or sarecycline for ≤3 months, then taper off and continue topicals. For females, combined OCP or spironolactone (50–200 mg/day) is an equivalent or preferable alternative to oral antibiotics.
• Severe (nodulocystic, scarring, fails to respond, deep psychosocial burden): isotretinoin, started by a dermatologist, cumulative dose 120–150 mg/kg over 5–7 months, with monthly pregnancy testing for females (US iPLEDGE; equivalent programmes in EU/UK).

Adjuncts apply at every tier: gentle non-soap cleanser twice daily; non-comedogenic moisturiser (retinoid use makes this non-negotiable); broad-spectrum SPF 30+ (retinoids and doxycycline both raise photosensitivity); do not pick lesions, as mechanical disruption is the single largest modifiable driver of atrophic scarring and post-inflammatory hyperpigmentation Tan 2017. Treatment is judged at 12 weeks, not 2 weeks; the initial 2–6 weeks often involves transient worsening ("purging").

contraindications

Isotretinoin is the major one. It is category X teratogenic — even one dose during pregnancy causes severe craniofacial, cardiac, and CNS malformations; pregnancy must be excluded before each prescription and two methods of contraception used for one month before, during, and one month after treatment under iPLEDGE Reynolds 2024. Tetracyclines (doxycycline, minocycline) are contraindicated under age 8 and in pregnancy (permanent tooth discolouration, skeletal effects); doxycycline raises photosensitivity substantially. Topical retinoids are pregnancy-category-C and should be discontinued if pregnancy is planned. Combined OCPs require screening for thrombosis risk (smoking, migraine with aura, personal/family VTE history). Spironolactone requires baseline potassium check in patients on ACE-inhibitors, ARBs, or with renal impairment.

misconceptions

The conventional teen-acne folklore is mostly wrong and often actively harmful Tan 2018:

• "Acne is caused by dirt / not washing enough." Acne is an inflammatory disease of sebum production and follicular plugging. Over-washing makes it worse — it strips the lipid barrier, drives reflex sebum upregulation, and irritates lesions. Twice-daily gentle cleansing is the ceiling.
• "Chocolate / fatty food causes acne." The chocolate-acne link in trials is weak to absent. The dietary signals that do hold up are high-glycemic-load diets (a 12-week low-glycemic RCT reduced lesion counts ~50%) Smith 2007 and skim milk specifically (cohort association, plausible via IGF-1) Adebamowo 2005 — but the effect size is far smaller than topicals deliver, and diet alone is not adequate treatment.
• "It'll resolve on its own, no need to treat." Untreated moderate-to-severe acne scars permanently in roughly 30–50% of cases; scars are largely irreversible and orders of magnitude more expensive to address later than the original disease Tan 2017.
• "Tanning / sun clears acne." A short-term anti-inflammatory illusion that worsens post-inflammatory hyperpigmentation, accelerates scarring, and raises long-term skin cancer risk.
• "Popping a pimple makes it heal faster." Mechanical disruption ruptures the follicle into the dermis, deepens the inflammatory response, and is the single most common cause of ice-pick scarring.
• "Isotretinoin causes depression and suicide." Causality is not supported. A 2017 meta-analysis (n=2,300+) found depressive-symptom scores actually improved on isotretinoin Huang & Cheng 2017; the Swedish national cohort (n=5,756 isotretinoin users) found the elevation in suicide attempts began before treatment, peaked during, and returned to baseline within 3 years — consistent with severe acne driving the risk, not the drug Sundström 2010. The FDA black box stays in place; the clinical practice is to monitor mood and counsel families, not to withhold the most effective treatment from a teenager whose disease is itself the bigger psychiatric exposure.

stakes

Two layers, both well-evidenced and routinely undersold by adults who say "they'll grow out of it." Scarring: atrophic scars (ice-pick, boxcar, rolling) form when inflammation reaches the dermis and is sustained; once formed they are functionally permanent and require laser, microneedling, subcision, or filler to soften — none of which restore baseline. Risk scales with severity, duration, and mechanical disruption (picking). Across cohorts, ~30–55% of moderate-to-severe cases develop visible scarring; the window to prevent it is the window of active disease Tan 2017. Mental health: the Norwegian HUNT-3 study (n=3,775 18–19-year-olds) found substantial acne associated with adjusted odds of 1.80 (girls) and 1.97 (boys) for suicidal ideation — the strongest skin-disease–mental-health signal in adolescent epidemiology Halvorsen 2011. A UK primary-care cohort of 134,000 acne patients found a 63% relative increase in incident major depression in the first year after diagnosis (HR 1.63) Vallerand 2018. Acne severity tracks with social withdrawal, lower educational attainment, higher unemployment risk — second-order effects of years of avoiding photos, mirrors, and peer attention during the period self-concept is being built.

payoff

The face under the breakouts is the same face. Treatment that works gives it back. With BPO + topical retinoid as first-line, lesion counts drop ~40–60% at 12 weeks; the addition of oral therapy for moderate disease pushes that further. Isotretinoin produces durable remission in roughly 80% of severe cases — the closest thing to a cure in dermatology Reynolds 2024. The psychiatric payoff is large and fast: the same Swedish cohort that found pre-treatment suicidal ideation found it dropped to background within 6 months of clearance Sundström 2010; QoL scores on Cardiff Acne Disability Index normalise within months once visible lesions resolve. The scars don't reverse — but post-inflammatory hyperpigmentation (the brown / red marks that persist after a lesion heals) fades with retinoid use and time. Time-to-felt-effect: 2 weeks for less pain at the lesion sites, 6–8 weeks for fewer new lesions, 12 weeks for the first visible turn, 5–7 months for the fullest result.

practicalities

Most of the ladder is cheap and accessible. Adapalene 0.1% and benzoyl peroxide 2.5–5% are both OTC in most countries (US since 2016); a year's supply runs $40–120. Oral doxycycline, OCPs, and spironolactone are generic and inexpensive on insurance or under most healthcare systems. The expense and access friction is isotretinoin: dermatologist visits, monthly bloodwork (LFTs, triglycerides) and pregnancy tests for females, and registry programmes (iPLEDGE in the US — known for clunky digital workflow). Even so, a 5–7 month isotretinoin course typically costs in the low thousands without insurance and is widely covered. The bigger friction is adherence: the topicals work only when used nightly, every night, for months — most teens stop at 4 weeks when nothing has changed visibly. Setting expectations explicitly at the start (initial purge, 12-week judgement window, lifetime risk of scarring if undertreated) is the single largest deterministic gain a clinician can produce.

audience

The brief is adolescent acne, but the staging differs by puberty stage and by sex. Pre-pubertal acne (under 8) is rare and prompts workup for hyperandrogenism (adrenal tumour, congenital adrenal hyperplasia) Eichenfield 2013. Early adolescent acne (9–13) is increasingly common as puberty has shifted earlier — guidelines now treat it the same as adolescent acne. Female adolescents with persistent acne, hirsutism, or menstrual irregularity warrant PCOS screening (free testosterone, DHEA-S, 17-OHP, pelvic ultrasound); hormonal therapy (OCP, spironolactone) becomes a strong second-line. Skin of colour faces a different scarring profile — post-inflammatory hyperpigmentation is the dominant complication, often more distressing and persistent than the original lesions, and earlier aggressive treatment is warranted. Truncal acne (back, chest) is often underreported because it's hidden but responds to the same therapies; large-area BPO washes are the practical addition.

failure-modes

The common failure patterns:

• Stopping at 4 weeks. Topicals look like they're doing nothing until ~8 weeks. The 12-week judgement window is non-negotiable.
• Over-stripping. Layering BPO + retinoid + salicylic-acid toner + alcohol toner inflames the barrier and produces irritation that looks like the acne worsening — leading to more product, not less.
• Picking. The single largest determinant of scarring after disease severity itself Tan 2017. Pickers need an explicit behavioural plan, not just "stop."
• Oral-antibiotic monotherapy. Drives resistance; the guideline mandates concurrent BPO Reynolds 2024.
• Tanning beds. Adolescents and parents both still believe sun "dries it up." It worsens hyperpigmentation, scarring, and skin cancer risk.
• Comedogenic skincare and makeup. Heavy oils, shea-butter heavy formulations, and certain silicones plug follicles; non-comedogenic-labelled product is a baseline.
• Sports / occlusion ("acne mechanica"). Helmets, hat bands, backpack straps, prolonged mask-wearing produce friction acne on the forehead, jaw, and back.

out-of-scope

Adult female acne (covered partially via hormonal therapy here but mechanism, age trajectory, and PCOS context warrant their own entry); rosacea (distinct disease, no comedones, different treatment); hidradenitis suppurativa (folliculitis of the apocrine areas — different mechanism, biologics-relevant). Mechanical / occupational acne in older populations. Acne scar revision procedures (laser, microneedling, subcision, dermal fillers) — substantial enough to warrant their own entry.

The credibility range

The optimist case. Adolescent acne is the dermatology success story of the last 40 years. The pathophysiology is mapped at high resolution (microcomedone, TLR2, IL-17, biofilm), the ladder is supported by Cochrane-level evidence, isotretinoin is one of the most effective drugs in medicine for its indication, and the gap between best practice and average care is the only remaining variable. Cleared early, scarring is largely preventable; cleared at all, the mental-health payoff is fast and large. The honest message is "treat aggressively, treat early, escalate without apology when the topicals aren't enough" — and the catalogue should say so.

The skeptic case. Most acne resolves with puberty regardless of treatment; the natural history is benign and self-limited in most cases. RCTs are short (12 weeks), measure surrogate endpoints (lesion counts), and pre-select compliant participants — the under-25% adherence rates in the community mean real-world effect sizes are smaller than trial effect sizes suggest. The mental-health associations are confounded (acne severity correlates with low socioeconomic status, poor sleep, family stress, all of which independently predict depression); isotretinoin's mental-health safety is reassured at the population level but individual paradoxical reactions occur. Aggressive treatment of mild cases over-medicalises a normal pubertal phenotype, and oral antibiotics for moderate cases drive resistance with population-level harms (skin and gut microbiome disruption, antimicrobial stewardship).

Author's call. The optimist case wins on the consequence axis — scarring and mood — and the skeptic case wins on the prescribing-restraint axis (antibiotics, mild-case over-treatment). The synthesis: treat aggressively when scarring or mood signal is present, treat conservatively when neither is, never use oral antibiotic monotherapy or extend beyond 3 months, and route the moderate-to-severe cases to a dermatologist before scarring forms — not after. Evidence rating 5, controversy rating 1 (the field is largely aligned on the framework above; what's contested is antibiotic stewardship details and isotretinoin dosing schemes, not the basics).

Stakeholder + incentive map

• Commercial. Topical pharma (Galderma, Almirall, Sun) markets newer retinoids (trifarotene, adapalene–BPO combos) at premium price. Skincare industry markets a vast "acne" segment to teens, much of it ineffective at best (clay masks, charcoal) and harmful at worst (high-alcohol toners, mechanical scrubs). iPLEDGE generates compliance overhead but exists to keep isotretinoin available.
• Professional. AAD, AAP, ESDR, NICE align on the four-tier ladder; minor disagreements on antibiotic duration (US AAD ≤3 months, UK NICE up to 6 with BPO) and isotretinoin micro-dosing.
• Community. Reddit r/SkincareAddiction and r/acne (~3M combined subscribers) have a strong pro-retinoid, anti-antibiotic, pro-isotretinoin consensus that converges with current guidelines — community got there first on some specifics (adapalene OTC, BPO 2.5% over 10%).
• Counter / skeptic. A small "natural acne" wellness industry pushes diet, gut-microbiome, supplement protocols; weak evidence base; commercially incentivised. Anti-isotretinoin advocacy persists (largely US, parent-driven, pre-dating the Huang 2017 meta-analysis).

Population variability

• Sex / hormones. Female adolescents have wider treatment options (OCP, spironolactone) and a stronger hormonal-acne phenotype (jawline, perimenstrual flares). PCOS screening warranted for the resistant, hirsute, or oligomenorrheic subset.
• Skin of colour. Post-inflammatory hyperpigmentation is the dominant complication, often more persistent than the original lesion. Treatment thresholds are lower; sun protection is more important. Hydroquinone and azelaic acid are useful adjuncts.
• Age. Pre-pubertal acne (under 8) is rare and triggers endocrine workup. Persistence into the mid-20s ("post-adolescent acne") is increasingly common in females.
• Genetics. Heritability ~80% by twin studies; family history of severe nodulocystic acne raises the threshold for early aggressive treatment.
• Diet / lifestyle. High-glycemic-load diets and skim milk worsen acne modestly across heterogeneous populations; effect sizes are smaller than topicals and the intervention is adjunctive at most.

Knowledge gaps

• Optimal duration and tapering schedule for isotretinoin remains debated; low-dose long-duration regimens may match standard-dose courses with fewer side-effects but evidence is mixed.
• Microbiome-based interventions (oral or topical probiotics, phage therapy targeting C. acnes) are mechanistically intriguing but lack adequate RCTs as of 2024.
• Long-term mental-health outcomes after acne clearance in adolescence — does the social-functioning deficit fully recover, or does the years-of-avoidance pattern leave a residual? Cohort follow-up is short.
• The exact contribution of dietary glycemic load and dairy is real but small; the precise effect sizes and which populations respond remain underspecified.
• Truncal acne is under-studied; most RCTs measure facial lesion counts only.
• Best non-isotretinoin option for severe scarring-prone disease in patients where isotretinoin is contraindicated — no clear winner.

Scoping calls

• The brief named four consequences (skin, scarring, mood/self-esteem, social functioning); the article covers all four. Skin and scarring are the spine of mechanism, evidence, stakes, protocol, payoff. Mood and self-esteem land in stakes (Halvorsen 2011 OR 1.80/1.97 for suicidal ideation; Vallerand 2018 HR 1.63 for incident depression) and payoff (the Swedish-cohort signal that elevated suicide-attempt rates drop to background as clearance arrives). Social functioning is the closing beat of stakes and the "version of them that walks back into group photos" line in payoff — deliberately not pinned to a single RCT because the social-habit literature is observational at best.
• The treatment ladder is treated as the entry's central protocol, not as a separate companion entry. Adolescent acne and its treatment ladder are too interlocked to split — separating "the disease" from "what to do about it" would force the reader to navigate two entries to get the actionable picture, and the brief explicitly named the ladder as in-scope.
• Adult-onset female acne is flagged in out-of-scope but not covered. Shares mechanism with the hormonal-pattern half here, but the age trajectory and the PCOS workup deserve their own entry rather than being absorbed into a teen-focused piece.
• Acne scar revision (laser, microneedling, subcision, filler) is out of scope. The entry covers prevention — the window is the active disease. Revision procedures are a different decision tree for the adult living with what an undertreated adolescence left behind, and warrant a separate entry. Flagged in out-of-scope and listed below as a separate-entry candidate.
• Diet (low-glycemic, dairy) is handled in misconceptions, not as a primary lever. The Smith 2007 and Adebamowo 2005 signals are real but small relative to topicals; treating diet as a top-level protocol misallocates emphasis. Covered honestly without overselling.

Rating difficulties

• beauty_cumulative at 5 vs 4. Landed on 5 because the entry's central pivot is preventing permanent scarring — the trajectory-changing consequence the dimension's 5 anchor describes ("reverses or prevents an entire trajectory of accumulated visible damage"). The window-once nature of scar prevention is what justifies the top of the ladder; a 4 would understate the asymmetry the article hinges on.
• mood at 4 vs 5. 4 fits — the literature is unambiguous about substantial effect on adolescent depression/suicidal ideation, but acne is one driver among several, and clearance doesn't address depression with other causes. A 5 would imply psychiatric-intervention-tier effect on inner wellbeing generally, which overstates what clearance delivers.
• health_short_term at 2. Tempted to score 0 — acne isn't a "wellness" condition in the way the dimension usually means. Settled on 2 because there is a real felt-experience component: cysts hurt, pain is reduced, the daily-coping load drops. Not big, but not nothing.
• applicability at 3. Borderline between 3 and 4. ~85% lifetime prevalence in 12–24-year-olds (Bhate & Williams 2013) reads like a high number, but the catalogue's reader is adult, and the decision audience is "currently has it / is a parent of someone who does" — large minority, not most-adults. 3 is honest.
• cadence = course vs daily. The topicals are nightly forever-during-the-disease, which reads like daily; chose course because the disease has a defined endpoint (clearance in late adolescence or after an isotretinoin course) and the cadence vocabulary's course anchor — "time-limited bounded course with a defined endpoint" — fits the treatment arc better than the topical-application rhythm fits daily.
• action = respond. Considered do. respond is the better fit — the action triggers when the condition presents, rather than being a maintained-by-everyone habit like sleep hygiene.

Dream narrative — by choice at borderline tier

Overall score by the §1 formula lands at ≈26, below the 40 obligation. Wrote one anyway because the relief / what-you-keep lever is genuinely strong here (the unscarred adult face, the photos that go back on the fridge), and the dek and tagline both gain from being projected through it. Lever picked per dream-narrative.md §3: relief, not aspiration — the dream is what the reader gets to keep, not a transformed life.

Future-link candidates

• Adult-onset acne in women / hormonal acne — sibling entry, would cross-link from this entry's audience female-scoped subsection.
• PCOS — referenced in audience; warrants its own entry; would cross-link.
• Isotretinoin — strong candidate for its own entry given complexity, iPLEDGE detail, and persistent folklore around mood effects.
• Acne scar revision (laser, microneedling, subcision, filler) — flagged in out-of-scope; the procedural side is substantial enough to stand alone.
• Skin-of-colour-specific scarring (post-inflammatory hyperpigmentation) — could expand into its own entry on PIH from any cause (acne, eczema, friction).
• Hydrocolloid pimple patches — flagged briefly in failure-modes as a picking-prevention tool. Mild, low-evidence on lesion resolution but useful behaviourally.
• Low-glycemic diet for skin — small future entry on the Smith 2007 / Adebamowo 2005 lineage. Real but small effect.

Separate-entry candidates

• Adult-onset / hormonal acne in women
• Isotretinoin (the drug, in depth)
• Acne scar revision procedures
• Post-inflammatory hyperpigmentation